Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, February 9, 2024

What’s on the recovery and rehabilitation horizon? The third international Stroke Recovery and Rehabilitation Roundtable (SRRR3) initiative

 I saw NOTHING on research to 100% recovery in the first 2!  I'd have you all fired for incompetence in not getting to 100% recovery!

What’s on the recovery and rehabilitation horizon? The third international Stroke Recovery and Rehabilitation Roundtable (SRRR3) initiative

https://doi.org/10.1177/17474930231218329
  • PDF / ePub
  • In this month’s issue of the International Journal of Stroke (IJS), we have a focus on stroke recovery and rehabilitation, covering both the third international Stroke Recovery and Rehabilitation Roundtable (SRRR3) consensus statements and recent related work published in the journal. The recommendations of SRRR3 were officially launched at the 2023 World Stroke Congress in Toronto, Canada.
    The roundtables are an initiative of the International Stroke Recovery and Rehabilitation Alliance (ISRRA).1 This third roundtable effort builds on the first and second SRRR initiatives to address new areas where consensus was needed to support progress in the field of stroke recovery and rehabilitation. The first roundtable covered definitions,2 biomarkers,3 standardized measurement of sensorimotor recovery,4 preclinical and clinical alignment,5 and monitoring and reporting of stroke recovery research.6 The second addressed consensus concerning trial development,7 cognition,8 translation into clinical practice,9 and standardized measurement of quality of movement.10 The third roundtable focused on control comparator trial design,11 fatigue,12 non-invasive brain stimulation,13 and standardized measurement of balance and mobility.14 A global initiative and undertaking, SRRR3 included over 50 experts from more than 20 countries around the world. Each SRRR3 taskforce topic for consensus will be discussed in turn and linked to recent studies in the journal.
    Control comparator selection is a critical trial design issue. The benefit of an experimental intervention is established relative to a prespecified comparator. Poor selection can diminish the effect observable. To improve preclinical and clinical control comparator decision-making during trial development, this taskforce11 developed the CONtrol DeSIGN (CONSIGN) decision support tool (https://www.redcap.link/SRRR-CONSIGN). This tool was designed to address common control design challenges faced by trialists. These included selecting an appropriate type of control, managing threats to internal validity, and understanding the content of the control and how it differs from the experimental intervention. There is no one-size-fits-all control comparator design. Recent stroke recovery and rehabilitation studies published in the IJS demonstrate the breadth of controls used.1517 This taskforce did define each type of control and when it is useful; it is a handy reference table for all trialists.
    The global pooled prevalence of fatigue after stroke is 46.9% (95% confidence interval = 43.4–50.8%).18 Despite the high burden of fatigue, progress in the field has been hampered by inconsistent definitions, outcome measures, and trial findings. The multidisciplinary fatigue taskforce12 produced a roadmap for future research. They presented a consensus definition, “a feeling of exhaustion, weariness or lack of energy that can be overwhelming, and which can involve physical, emotional, cognitive and perceptual contributors, which is not relieved by rest and affects a person’s daily life,” and tackled four priority areas: (1) best measurement tools for research, (2) clinical identification of fatigue and potentially modifiable causes, (3) promising interventions and recommendations for future trials, and (4) possible biological mechanisms of fatigue. The taskforce recommended outcome measures to use in studies of post-stroke fatigue, screening of all stroke patients using a new Stroke Fatigue Clinical Assessment Tool, highlighted priority therapies to examine for future research, and priority areas for understanding the biology of post-stroke fatigue. Some priorities for intervention development and testing (e.g. pharmacological interventions19 and exercise20) and understanding biology (e.g. neuroimaging correlates21) align with recent IJS papers.
    Another taskforce was established to develop consensus recommendations to identify and address outstanding translational bench-bedside barriers and provide a roadmap for the use of transcranial magnetic stimulation and transcranial Direct Current Stimulation for stroke recovery and rehabilitation.13 Recommendations highlight an urgent need for an increased understanding of non-invasive brain stimulation mechanisms, improved methodological rigor in both preclinical and clinical non-invasive brain stimulation studies, standardization of outcome measures, increased clinical relevance in preclinical animal models, and greater optimization and individualization of non-invasive brain stimulation protocols. To facilitate the implementation of these recommendations, the expert panel developed a new SRRR3 Unified Non-Invasive Brain Stimulation Research Checklist.
    Although prospective epidemiological studies are lacking, mobility problems are experienced by 80% of stroke survivors. After 3 months, 40% of initially non-ambulatory stroke survivors are either unable to walk or dependent on assistance of a person, whereas 30–80% experience a fall within the first 4 years post-stroke.22 The present consensus recommendations established a standardized set of clinical measurement instruments for investigating lower limb motor function, sitting- and standing-balance, and mobility. These can be considered with other work regarding measurement of physical activity post-stroke.23 Testing protocols were added to this roundtable to ensure the same clinical tests were implemented consistently. Furthermore, how to define the underlying constructs and which baseline characteristics to assess were recommended at timepoints in line with previous recommendations.2 Finally, kinetic and kinematic metrics, including their equipment, were recommended to monitor recovery of quality of movement during standing and walking post-stroke. The recommendations serve to support harmonization of data collection, which will improve the comparability between studies and support establishment of big balance and mobility data sets post-stroke. Only then phenotyping recoverers and non-recoverers of lower limb recovery2426 and identifying responders of a therapy22 may give more robust answers in the future.
    The completed roundtables add to the growing library of roundtable recommendations that can (and are) being used to guide the stroke recovery and rehabilitation research. The themes to date have spanned harmonization of terminology and outcomes, clinical trial design and conduct, and neglected domains of cognition and fatigue, with a cross-cutting theme of preclinical–clinical alignment as many roundtables have approached their taskforce by integrating knowledge and skills across the translational pipeline. Increasingly, consensus efforts are shaping the focus and methods of recovery and rehabilitation research. Our hope is that research funders and research teams pay attention to the priority targets and methodological rigor that is called for in these statements and that international collaboration drives new discoveries that benefit the millions of survivors each year who are impacted by stroke.
    Kathryn S Hayward
    The University of Melbourne, Melbourne, VIC, Australia
    Email: Kate.hayward@unimelb.edu.au
    Julie Bernhardt
    The Florey, Melbourne, VIC, Australia
    Gert Kwakkel
    Amsterdam University Medical Centre, Amsterdam, The Netherlands

    No comments:

    Post a Comment